User menu

Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: Results from the ESCAPE study

Bibliographic reference Bervoets, C ; Morrens, M ; Vansteelandt, K ; Kok, F ; De Patoul, A ; et. al. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: Results from the ESCAPE study. In: CNS Drugs, Vol. 26, no.11, p. 975-982 (november 2012)
Permanent URL
  1. Leucht Stefan, Corves Caroline, Arbter Dieter, Engel Rolf R, Li Chunbo, Davis John M, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, 10.1016/s0140-6736(08)61764-x
  2. Harvey Philip D., Keefe Richard S.E., Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment, 10.1176/appi.ajp.158.2.176
  3. Keefe Richard S. E., Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial, 10.1001/archpsyc.64.6.633
  4. Green Michael F., Kern Robert S., Heaton Robert K., Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS, 10.1016/j.schres.2004.09.009
  5. Woodward Neil D., Purdon Scot E., Meltzer Herbert Y., Zald David H., A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects, 10.1016/j.schres.2006.08.021
  6. Burris K. D., Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors, 10.1124/jpet.102.033175
  7. Jordan Shaun, Koprivica Vuk, Chen Ruoyan, Tottori Katsura, Kikuchi Tetsuro, Altar C.Anthony, The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor, 10.1016/s0014-2999(02)01532-7
  8. Jordan Shaun, Koprivica Vuk, Dunn Robert, Tottori Katsura, Kikuchi Tetsuro, Altar C.Anthony, In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function, 10.1016/j.ejphar.2003.10.025
  9. Kane John M., Carson William H., Saha Anutosh R., McQuade Robert D., Ingenito Gary G., Zimbroff Dan L., Ali Mirza W., Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder, 10.4088/jcp.v63n0903
  10. Kasper Siegfried, Lerman Mark N., McQuade Robert D., Saha Anutosh, Carson William H., Ali Mirza, Archibald Donald, Ingenito Gary, Marcus Ronald, Pigott Teresa, Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia, 10.1017/s1461145703003651
  11. Croxtall Jamie D., Aripiprazole : A Review of its Use in the Management of Schizophrenia in Adults, 10.2165/11208400-000000000-00000
  12. Riedel M., Spellmann I., Schennach-Wolff R., Musil R., Dehning S., Cerovecki A., Opgen-Rhein M., Matz J., Seemüller F., Obermeier M., Severus E., Engel R. R., Müller N., Möller H.-J., Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia, 10.1055/s-0029-1239539
  13. Kim Chang Yoon, Chung Seockhoon, Lee Joon-Noh, Kwon Jun Soo, Kim Do Hoon, Kim Chul Eung, Jeong Bumseok, Jeon Yang-Whan, Lee Min-Soo, Jun Tae-Youn, Jung Hee-Yeon, A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder : , 10.1097/yic.0b013e32832c25d7
  14. Peuskens J, Bervoets C, Kok F, et al. A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia. Eur Psychiatry. Epub 2011 Sept 13.
  15. VASKINN ANJA, SUNDET KJETIL, FRIIS SVEIN, UELAND TORILL, SIMONSEN CARMEN, BIRKENAES ASTRID B., ENGH JOHN A., OPJORDSMOEN STEIN, ANDREASSEN OLE A., Can learning potential in schizophrenia be assessed with the standard CVLT-II? An exploratory study, 10.1111/j.1467-9450.2008.00627.x
  16. Gueorguieva Ralitza, Krystal John H., Move Over ANOVA : Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in theArchives of General Psychiatry, 10.1001/archpsyc.61.3.310
  17. Wolfinger R, Chang M. Comparing the SAS GLM and MIXED procedures for repeated measures. Cary: SAS Institute Inc.; 1998.
  18. Russell D, Wolfinger R. Fitting nonlinear mixed models with the new NLMIXED procedure: repeated measures. Cary: SAS Institute Inc.; 1997.
  19. Keselman H. J., Algina James, Kowalchuk Rhonda K., Wolfinger Russell D., A comparison of two approaches for selecting covariance structures in the analysis of repeated measurements, 10.1080/03610919808813497
  20. What are the functional consequences of neurocognitive deficits in schizophrenia?, 10.1176/ajp.153.3.321
  21. Bozikas Vasilis P., Kosmidis Mary H., Peltekis Apostolos, Giannakou Maria, Nimatoudis Ioannis, Karavatos Athanasios, Fokas Kostas, Garyfallos George, Sex Differences in Neuropsychological Functioning Among Schizophrenia Patients, 10.3109/00048670903489833
  22. Wobrock T., Köhler J., Klein P., Falkai P., Achieving symptomatic remission in out-patients with schizophrenia - a naturalistic study with quetiapine, 10.1111/j.1600-0447.2009.01379.x
  23. Popolo Raffaele, Vinci Giancarlo, Balbi Andrea, Cognitive function, social functioning and quality of life in first-episode psychosis: A 1-year longitudinal study, 10.3109/13651500903282881
  24. Harvey Philip D., Hassman Howard, Mao Lian, Gharabawi Georges M., Mahmoud Ramy A., Engelhart Luella M., Cognitive Functioning and Acute Sedative Effects of Risperidone and Quetiapine in Patients With Stable Bipolar I Disorder : A Randomized, Double-Blind, Crossover Study, 10.4088/jcp.v68n0804
  25. Mohamed Somaia, Rosenheck Robert, Swartz Marvin, Stroup Scott, Lieberman Jeffrey A., Keefe Richard S.E., Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia, 10.1176/appi.ajp.2008.07111713